ClinicalTrials.gg
RecruitingNCT05939219Updated Jul 12, 2023

Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine

An interventional study of 15-valent pneumococcal conjugate vaccine 202210001 and 15-valent pneumococcal conjugate vaccineY202210002 in Healthy Volunteers, sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 3 Months to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-12.

Sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (part of Chongqing Zhifei Biological Products Co., Ltd.) · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,346
Allocation
Randomized
Ages
3 Months to 5 Years
Sex
All
01

Study summary

The objective of this clinical trial is to evaluate the consistency of the 15-valent pneumococcal conjugate vaccine in three batches of the 3-month-old population, as well as the immunogenicity and safety of vaccination in the 7-5-year-old population

Read the detailed description

The purpose of this experiment

  1. evaluate the consistency of clinical immune efficacy of three batches of commercially produced 15-valent pneumococcal conjugate vaccines.
  2. Compare the immunogenicity of commercial scale produced 15-valent pneumococcal conjugate vaccines in the 3-month-old population with the immunogenicity (non inferiority) of pilot scale produced 15-valent pneumococcal conjugate vaccines, that is, a clinical bridging study between commercial scale vaccines and Phase III clinical trial vaccines.
  3. Evaluate the immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine in the 7-5-year-old population after vaccination.

The commercial three batches and pilot scale batches were designed using a randomized, double-blind, parallel controlled trial of different batches of vaccines. The commercial three batches adopt equivalence design, and the immunogenicity results of the three batches are merged on the basis of equivalence, and compared with the immunogenicity of the pilot scale batch for non-inferiority.

Compare the immunogenicity data of the 7-5-year-old population experimental group with the immunogenicity results of the 3-month-old group (after merging three commercial batches on an equivalent basis) at the basic immune stage for non-inferiority.

At the same time, a positive control was established in the 7-month-5-year-old population, and a randomized, blind design was used to compare the immunogenicity of the experimental group and the control group in this age group.

The study population consists of a total of 2346 people, including 1104 people at the age of 3 months, divided into four groups with 276 people in each group. They were assigned to batch 1, batch 2, batch 3, and the pilot scale module at a ratio of 1:1:1:1. There are a total of 1242 people aged 7 months to 5 years old, divided into three age groups: 7-11 months old, 12-23 months old, and 2-5 years old, with 414 people in each age group. Three age groups of participants were randomly assigned to the experimental group or control group in a 2:1 ratio. The experimental group received a 15-valent pneumococcal conjugate vaccine (batch 3), while the control group received a 13-valent pneumococcal polysaccharide conjugate vaccine produced by Yuxi Watson Biotechnology Co., Ltd. Among them:

  1. 3 months old: Basic immunization according to the 0, 1, and 2 month program (window period:+10 days); Strengthen immunization with 1 dose at the age of 12-15 months.
  2. 7-11 months of age: basic immunization with a 0 to 2-month program (window period:+10 days); After 12 months of age, strengthen the vaccination with 1 dose (3rd dose), with a minimum interval of 2 months between the 2nd dose.
  3. 12-23 months old: Immunize with 2 doses of 0 and 2 month program. The interval between two doses of vaccination should be at least 2 months (window period:+10 days).
  4. 2-5 years old: receive 1 dose.
02

Conditions studied

  • Healthy Volunteers

Keywords

  • 15-valent pneumococcal conjugate vaccine
03

In context

Lead sponsor

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd is the lead sponsor of 22 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy infants and children aged 3 months, 7 months, and 5 years old;
  • Infants under 1 year old should be born at full term (37 to 42 weeks of pregnancy) and have a birth weight within the range of (2500g ≤ body weight ≤ 4500g);
  • After , the Legal guardian voluntarily signs the informed consent form and can comply with the requirements of the clinical research scheme;
  • The subject has no history of receiving other within ≤ 14 days, and no history of receiving other non live vaccines within ≤ 7 days;
  • Underarm temperature ≤ 37.0 ℃.

Exclusion criteria

Exclusion Criteria:

  • Previously received commercially available or experimental pneumococcal vaccines;
  • Have a history of invasive disease caused by Streptococcus pneumoniae that has been confirmed by culture in the past;
  • Have a history of severe allergies to vaccines or medication;
  • Have a history of Nervous system disease such as convulsion, epilepsy, nervous system tumor, craniocerebral trauma, psychiatric history or family history;
  • Babies born under the age of 1 year with severe abnormal birth process (such as instrumental delivery) or a history of asphyxia or neurological organ damage;
  • Patients with pathological jaundice confirmed by current diagnosis;
  • A history of clearly diagnosed thrombocytopenia or other coagulation disorders may lead to for injection;
  • Immunoglobulin or any blood products (except immunoglobulin) were given within 3 months before enrollment;
  • Known or suspected to have immunological function defects, and received long-term drug treatment (radiotherapy, chemotherapy, , antimetabolics, cytotoxic drugs), infection or HIV infected parents within six months before vaccination;
  • Having severe congenital malformations, severe malnutrition, developmental disorders, or genetic defects (such as broad bean disease);
  • Currently suffering from serious chronic disease, infectious disease, active infection, liver disease, kidney disease, cardiovascular disease, and malignant tumor;
  • Absence of spleen or deficiency of spleen function caused by any circumstances;
  • Systemic rash, skin ringworm, skin suppuration or blisters;
  • Participating in other clinical trials;
  • Any situation that the researcher believes may affect the evaluation of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,346 participants (estimated)

Study arms

  • Experimental
    3-month-old group

    Randomly inoculate 4 batches of 15-valent pneumococcal conjugate vaccine. Immunization program and dosage: Basic immunization at 0, 1, and 2 months, booster immunization at 12-15 months of age, a total of 4 doses administered. Dosage form: water injection type

    Biological: 15-valent pneumococcal conjugate vaccine 202210001 · Biological: 15-valent pneumococcal conjugate vaccineY202210002 · Biological: 15-valent pneumococcal conjugate vaccineY202210003 · Biological: 15-valent pneumococcal conjugate vaccineY202210004

  • Experimental
    7-11 month old experimental group

    The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: Basic immunization for 0 and 2 months program; Strengthen one dose after 12 months of age; A total of 3 doses were administered. Dosage form: water injection type

    Biological: 15-valent pneumococcal conjugate vaccineY202210004

  • Active comparator
    7-11 month old control group

    The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: Basic immunization for 0 and 2 months program; Strengthen one dose after 12 months of age; A total of 3 doses were administered. Dosage form: water injection type

    Biological: 13 valent pneumococcal polysaccharide conjugate vaccine

  • Experimental
    12-23 months old experimental group

    The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: Immunize 2 doses using the 0 and 2 month program, with a total of 2 doses administered. Dosage form: water injection type

    Biological: 15-valent pneumococcal conjugate vaccineY202210004

  • Active comparator
    12-23 months old control group

    The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: Immunize 2 doses using the 0 and 2 month program, with a total of 2 doses administered. Dosage form: water injection type

    Biological: 13 valent pneumococcal polysaccharide conjugate vaccine

  • Experimental
    2-5 year old experimental group

    The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: 1 dose administered. Dosage form: water injection type

    Biological: 15-valent pneumococcal conjugate vaccineY202210004

  • Active comparator
    2-5 year old control group

    The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1. Immunization program and dosage: 1 dose administered. Dosage form: water injection type

    Biological: 13 valent pneumococcal polysaccharide conjugate vaccine

Interventions

  • Biological15-valent pneumococcal conjugate vaccine 202210001

    Immunization program and dosage:3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered

  • Biological15-valent pneumococcal conjugate vaccineY202210002

    Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered

  • Biological15-valent pneumococcal conjugate vaccineY202210003

    Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered

  • Biological15-valent pneumococcal conjugate vaccineY202210004

    Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered

  • Biological13 valent pneumococcal polysaccharide conjugate vaccine

    Immunization program and dosage: 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered

06

What researchers measure

Primary outcomes

  1. Geometric mean concentration of vaccine Serotype specific pneumococcal IgG antibody

    Immunogenicity evaluation

    Time frame: 30 days after basic immunization at 3 months old and 7-11 months old, and 30 days after full immunization at 12-23 months old and 2-5 years old

  2. Vaccine Serotype specific pneumococcal IgG antibody concentration ≥ 0.35 μg/ml of proportion of subjects

    Immunogenicity evaluation

    Time frame: 30 days after basic immunization at 3 months old and 7-11 months old, and 30 days after full immunization at 12-23 months old and 2-5 years old

07

Study locations

1 of 1 sites recruiting
  • Hebei Provincial Center for Disease Control and Prevention
    Shijiangzhuang, Hebei 050021, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Jan 2025, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2023
First posted
Jul 11, 2023
StartActual
Jul 1, 2023
Primary completionEst.
Jan 31, 2025
CompletionEst.
Jun 30, 2025
Last update
Jul 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05939219
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Jul 1, 2023
Primary completion
Jan 31, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Jul 12, 2023

Study contacts

Wenjian Fang, master
Contact
fangwenjian@zhifeishengwu.com
18611630252
Lin Du, master
study chair · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion